CRISPR Therapeutics AG (NAS:CRSP) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
CRISPR Therapeutics AG's Liquidation Value for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG Total Current Assets Related Terms
CRISPR Therapeutics AG Total Current Assets Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of $2,448.36 Mil mean?
CRISPR Therapeutics AG (CRSP) has a Total Current Assets of $2,448.36 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Total Current Assets too high?
CRISPR Therapeutics AG's current Total Current Assets is $2,448.36 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Total Current Assets compare to ORKA and TVTX?
CRISPR Therapeutics AG's Total Current Assets of $2,448.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Total Current Assets is $2,448.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $60.08 — trading 2061.2% above its estimated fair value. The current Total Current Assets is $2,448.36 Mil. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Total Current Assets is $2,448.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $60.08 is trading 2061.2% above its estimated GF Value™ of $2.78.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for CRSP:
Total Current Assets: $2,448.36 Mil
GF Value™: $2.78 vs. price of $60.08 (2061.2% above fair value)
No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score
Get the complete analysis for CRSP
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 
